Clinical trial Recruiting at 1 site Observational

Observing the natural history of a rare brain disorder called LBSL

Official title: Characterization of the Natural History of Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation

Run by Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · NCT03624374 · Data updated 2026-11-12

This study looks at how a rare brain disorder called LBSL affects movement and thinking in patients to better understand their challenges and improve their quality of life.

More Genetic Disease trials

Quick facts

Study typeObservational
SexAll
Enrollment100 (estimated)
SponsorHugo W. Moser Research Institute at Kennedy Krieger, Inc.
Academic / other
Locations1 site (Baltimore, Maryland)
StatusRecruiting
StartedApril 1, 2018
Main results expectedMay 2029
Study endsMay 2029
Registry record updatedJuly 3, 2024
Trial IDNCT03624374 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals with a confirmed DARS2 mutation and the ability to communicate in English at an 8th-grade level.

Probably not a fit

Patients who do not have a confirmed DARS2 mutation or those who cannot communicate in English may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on individuals diagnosed with leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL). It involves retrospective chart and imaging reviews, as well as prospective longitudinal virtual assessments to gather detailed information on the neurocognitive and neuromotor impairments associated with this rare genetic disorder. The study aims to identify the phenotypic spectrum of deficits, particularly in gait, and their impact on the quality of life of patients. Currently, there are no targeted therapies or established guidelines for supportive care in LBSL, making this research crucial for understanding the condition better.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the progression and impact of LBSL, potentially guiding future therapeutic approaches.

How similar studies have gone: While there is limited data on LBSL, similar observational studies in rare genetic disorders have provided valuable insights, suggesting potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Confirmed DARS2 mutation through genetic analysis
2. Ability of the caregiver or participant to speak and understand English at an 8th-grade level

Exclusion Criteria:

* The vulnerable populations of prisoners, non-viable neonates, pregnant women, adults lacking the capacity to consent, non-English speakers or children who are in foster care or wards of the state.

Where it's running

  • Hugo Moser Center for Leukodystrophies
    Baltimore, Maryland, United States
    Recruiting

Study contacts

  • Principal investigator: Amena S Fine, MD PhD — Moser Center for Leukodystrophies at Kennedy Krieger Institute
  • Study coordinator: Aditii Makwana, MS
  • Email: makwana@kennedykrieger.org
  • Phone: 667-205-4498

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.